News

Multimedia

Conferences

Publications

Brand Insights

Resources

Sustainability
DE&I
Pandemic
Finance
Legal
Technology
Regulatory
Global
Pricing
Strategy
R&D/Clinical Trials
Opinion
Executive Roundtable
Sales & Marketing
Executive Profiles
Leadership
Market Access
Patient Engagement
Supply Chain
Industry Trends

Podcast Interview: Chris Garabedian, CEO, AVI BioPharma

June 10, 2011

Article

In our latest podcast, Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.

Interview: Chris Garabedian

Chris Garabedian, CEO at AVI BioPharma, discusses his company's $291 million contract with the Defense Department, and how RNA-based therapeutics are being used to combat infectious diseases.

Related Content

FDA Grants Breakthrough Therapy Designation to Gilead’s Trodelvy for Extensive-Stage Small Cell Lung Cancer

Don Tracy, Associate Editor

December 18th 2024

Article

Breakthrough Therapy designation for Trodelvy was granted based on promising results from the Phase II TROPiCS-03 study, which showed encouraging antitumor activity in both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer.

FDA Approves Celltrion’s Stelara Biosimilar for Multiple Indications

Don Tracy, Associate Editor

December 18th 2024

Article

Approval of Steqeyma was based on a comprehensive evidence review, including a Phase III trial in moderate to severe plaque psoriasis.

Merck, Johnson & Johnson Submit Biologics License Applications for Pediatric Respiratory Syncytial Virus, Ulcerative Colitis

Don Tracy, Associate Editor

December 18th 2024

Article

New biologics license applications seek FDA approval for Merck’s clesrovimab to protect infants and children from respiratory syncytial virus and Johnson & Johnson’s Simponi for the treatment of ulcerative colitis.

FDA Approves Organon’s Vtama Cream, 1% for Atopic Dermatitis

Don Tracy, Associate Editor

December 17th 2024

Article

Approval of Vtama for atopic dermatitis provides a steroid-free treatment option for adults and pediatric patients.

FDA Grants Breakthrough Therapy Designation to GSK’s Jemperli for Locally Advanced Mismatch Repair Deficient/Microsatellite Instability-High Rectal Cancer

Don Tracy, Associate Editor

December 16th 2024

Article

The Breakthrough Therapy Designation for Jemperli was based on Phase II clinical trial data, showing a 100% clinical complete response rate in patients with locally advanced mismatch repair deficient/microsatellite instability-high rectal cancer.